Dorjiin Dandii

Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L

A. Bourinbaiar, Marina G Tarakanovskaya, V. Borisova, 2017, Journal of hepatocellular carcinoma.

Clinical experience with therapeutic vaccines designed for patients with hepatitis.

A. Bourinbaiar, V. Jirathitikal, Y. Dahgwahdorj, 2009, Current pharmaceutical design.

Interim results from ongoing Phase III placebo-controlled, randomized trial of hepcortespenlisimut-L for advanced hepatocellular carcinoma indication

A. Bourinbaiar, Marina G Tarakanovskaya, V. Borisova, 2020 .

Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C.

A. Bourinbaiar, V. Jirathitikal, Dorjiin Dandii, 2008, Vaccine.

Open Label Trial of Therapeutic Hepatitis B Vaccine V-5 Immunitor (V5)Delivered by Oral Route

A. Bourinbaiar, V. Jirathitikal, Dorjiin Dandii, 2007 .

Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L

A. Bourinbaiar, Marina G Tarakanovskaya, V. Borisova, 2017, Journal of hepatocellular carcinoma.